Saratoga Research & Investment Management increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,510,346 shares of the company’s stock after buying an additional 73,054 shares during the quarter. Novo Nordisk A/S comprises 5.4% of Saratoga Research & Investment Management’s holdings, making the stock its 6th largest position. Saratoga Research & Investment Management owned 0.06% of Novo Nordisk A/S worth $79,006,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at $232,000. LPL Financial LLC grew its stake in Novo Nordisk A/S by 1.3% during the 3rd quarter. LPL Financial LLC now owns 89,384 shares of the company’s stock worth $4,214,000 after purchasing an additional 1,159 shares in the last quarter. Brown Brothers Harriman & Co. grew its stake in Novo Nordisk A/S by 89.7% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 5,500 shares of the company’s stock worth $259,000 after purchasing an additional 2,600 shares in the last quarter. Glenmede Trust Co. NA grew its stake in Novo Nordisk A/S by 41.0% during the 3rd quarter. Glenmede Trust Co. NA now owns 255,650 shares of the company’s stock worth $12,050,000 after purchasing an additional 74,387 shares in the last quarter. Finally, NorthCoast Asset Management LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $2,503,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.
Shares of Novo Nordisk A/S stock traded down $0.17 on Friday, hitting $48.28. The stock had a trading volume of 1,712,334 shares, compared to its average volume of 1,345,799. Novo Nordisk A/S has a 52-week low of $41.23 and a 52-week high of $52.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.79 and a current ratio of 0.96. The company has a market capitalization of $118.39 billion, a P/E ratio of 19.16, a PEG ratio of 2.17 and a beta of 0.56.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/novo-nordisk-a-s-nvo-shares-bought-by-saratoga-research-investment-management.html.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Story: Stock Split
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.